Medicine and Dentistry
Age
16%
Cell Count
50%
Cells
50%
Highly Active Antiretroviral Therapy
50%
Human Immunodeficiency Virus
33%
Human Immunodeficiency Virus 1 Infection
16%
Human Immunodeficiency Virus Infection
16%
Immune Response
50%
Immunosuppressive Treatment
16%
Inpatient
33%
Marker
16%
Patient
50%
Prospective Cohort Study
50%
RNA
16%
Side Effect
33%
T Lymphocyte Subpopulation
16%
T-Helper Cell
100%
Therapeutic Procedure
50%
Immunology and Microbiology
Age
16%
CD38
16%
CD4 Lymphocyte Count
50%
Cells
50%
HLA-DR
16%
Human Immunodeficiency Virus
50%
Human Immunodeficiency Virus Infection
16%
Immune Response
50%
Immunity
33%
Recombinant Interleukin 2
66%
T Lymphocyte Subpopulation
16%
Biochemistry, Genetics and Molecular Biology
Age
16%
CD38
16%
CD4 Lymphocyte Count
50%
HLA-DR
16%
Human Immunodeficiency Virus
50%
Immune Response
50%
T Lymphocyte Subpopulation
16%
Neuroscience
CD38
16%
HIV
50%
HLA-DR
16%
RNA
16%
Suppression
16%
T Lymphocyte Subpopulation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Recombinant Interleukin 2
66%